Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Imagery rescripting treatment for OCD and BDD

Official title: Imagery Rescripting for Obsessive Compulsive Disorder and Body Dysmorphic Disorder: a Multiple-Baseline Single-Case Experimental Design.

Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT06346301 · Data updated 2026-11-12

This study is testing a new therapy called imagery rescripting to see if it can help people with Obsessive Compulsive Disorder and Body Dysmorphic Disorder feel better and change their negative thoughts.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment36 (estimated)
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Academic / other
Locations1 site (Amsterdam-Zuidoost, North Holland)
StatusRecruiting
StartedApril 21, 2023
Main results expectedJanuary 2026
Study endsJanuary 2027
Registry record updatedApril 4, 2024
Trial IDNCT06346301 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older who meet the DSM-5 criteria for OCD or BDD and have stable medication for at least six weeks.

Probably not a fit

Patients with current severe mental health issues such as active psychosis or suicidal plans may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of imagery rescripting (ImRs) as a treatment for Obsessive Compulsive Disorder (OCD) and Body Dysmorphic Disorder (BDD) through a multiple baseline case series design. Eighteen participants with OCD and eighteen with BDD will undergo a variable baseline period followed by a series of treatment sessions. The primary focus is on changes in core beliefs and symptoms, measured through various scales and qualitative interviews. The study aims to assess both immediate and longer-term effects of the intervention on patients' mental health.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce symptoms of OCD and BDD, improving patients' quality of life.

How similar studies have gone: While the approach of imagery rescripting is gaining interest, this specific application for OCD and BDD is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Meet the criteria for OCD or BDD, a primary diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
* Are aged 18 and beyond
* Dutch literacy
* Cut-off Y-BOCS of 20
* No change in medication. Stable dose at least 6 weeks prior to study.

Exclusion Criteria:

* Current (hypo)mania
* Active suicidal plans
* Current psychosis (excluding delusional symptoms related to disorder)
* Alcohol or drugs abuse as diagnosed by Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
* Electroconvulsive therapy in last 6 months
* Neurological disorder or Intelligence Quotient \< 80

Where it's running

  • Department of Psychiatry, AMC
    Amsterdam-Zuidoost, North Holland, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.